Yoshitaka Zenke

Yoshitaka Zenke

Auto-generated profile, based on publicly available information

Yoshitaka Zenke

Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
EIEiji Iwama
Eiji Iwama
YZYoshitaka Zenke
Yoshitaka Zenke
SSShunichi Sugawara
Shunichi Sugawara
HDHaruko Daga
Haruko Daga
MMMasahiro Morise
Masahiro Morise
IOIsamu Okamoto
Isamu Okamoto

6 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experimental Design: Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing. Results: Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months. Conclusions: Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA. See related commentary by Jacobsen Skanderup et al., p. 1381

1 September 2016 in Clinical Lung Cancer
Verified
Journal Article
Closed access
YZYoshitaka Zenke
Yoshitaka Zenke
KYKiyotaka Yoh
Kiyotaka Yoh
SMShingo Matsumoto
Shingo Matsumoto
SUShigeki Umemura
Shigeki Umemura
SNSeiji Niho
Seiji Niho
YOYuichiro Ohe
Yuichiro Ohe

14 February 2023 in Cancer Science
Verified
Journal Article
Open access
YFYutaka Fujiwara
Yutaka Fujiwara
RMReiko Makihara
Reiko Makihara
THTetsunari Hase
Tetsunari Hase
NHNaozumi Hashimoto
Naozumi Hashimoto
TNTomoyuki Naito
Tomoyuki Naito
NYNoboru Yamamoto
Noboru Yamamoto
The safety of osimertinib is limited in patients with severe or moderate renal impairment, or low body weight. This study aimed to investigate the safety, pharmacokinetics (PK) and recommended dose (RD) of osimertinib in patients with epidermal growth factor receptor (EGFR)‐mutated non–small cell lung cancer (NSCLC) with impaired renal function and low body weight. Thirty‐one eligible patients were enrolled and allocated into four cohorts: A, normal renal function (estimated glomerular filtration rate [eGFR] ≥ 50 mL/min/1.73 m2) and normal body weight (≥45 kg); B, moderate renal impairment (eGFR = 30‐50 mL/min/1.73 m2); C, low body weight (<45 kg); and D, severe renal impairment (eGFR <30 mL/min/1.73 m2 or undergoing dialysis). PK parameters and safety were evaluated with a starting dose of 80 mg osimertinib administered orally once daily in cohorts A, B, and C and 40 mg once daily in cohort D. The PK parameters in cohorts A, B, and C were found to be similar. No dose‐limiting toxicity was observed, and the RD was determined to be 80 mg once daily in patients with moderate renal function and low body weight. Four serious adverse events, acneiform rash, diarrhea, QTc prolongation, and interstitial lung disease, were noted. Although the PK parameters of osimertinib were similar across all cohorts, toxicity occurred more frequently in patients with impaired renal function and low body weight. Clinicians should prescribe osimertinib with caution in NSCLC patients with impaired renal function and low body weight.

1 June 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
YZYoshitaka Zenke
Yoshitaka Zenke
MTMasahiro Tsuboi
Masahiro Tsuboi
YCYasutaka Chiba
Yasutaka Chiba
KTKayoko Tsujino
Kayoko Tsujino
MSMiyako Satouchi
Miyako Satouchi
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
The standard curative treatment strategy for selected patients with locally advanced non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy with concurrent thoracic radiotherapy (TRT).1,2 The initial report of the West Japan Thoracic Oncology Group (WJTOG) 01053 trial establishes weekly carboplatin plus paclitaxel combined with TRT as the standard regimen among the 3 regimens because of its favorable toxic effect profile. Other studies found that concurrent chemoradiotherapy (CRT) with former-generation chemotherapy regimens achieved median survival of 16.1 to 30.0 months and 7-year overall survival (OS) rates ranging from 12.0% to 23.1%.4-6 However, limited data are available for patients who underwent concurrent CRT with third-generation chemotherapy who were followed up for more than 10 years.

10 October 2024 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SUShigeki Umemura
Shigeki Umemura
HUHibiki Udagawa
Hibiki Udagawa
TITakaya Ikeda
Takaya Ikeda
HMHaruyasu Murakami
Haruyasu Murakami
HDHaruko Daga
Haruko Daga
KGKoichi Goto
Koichi Goto